2.Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Pranavi KOPPULA ; Li ZHUANG ; Boyi GAN
Protein & Cell 2021;12(8):599-620
The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11
3.Cytochrome P450 reductase (POR) as a ferroptosis fuel.
Pranavi KOPPULA ; Li ZHUANG ; Boyi GAN
Protein & Cell 2021;12(9):675-679
4.Ferroptosis as an important driver of lupus.
Chao MAO ; Guang LEI ; Li ZHUANG ; Boyi GAN
Protein & Cell 2022;13(5):313-315
5.Ferroptosis, radiotherapy, and combination therapeutic strategies.
Guang LEI ; Chao MAO ; Yuelong YAN ; Li ZHUANG ; Boyi GAN
Protein & Cell 2021;12(11):836-857
Ferroptosis, an iron-dependent form of regulated cell death driven by peroxidative damages of polyunsaturated-fatty-acid-containing phospholipids in cellular membranes, has recently been revealed to play an important role in radiotherapy-induced cell death and tumor suppression, and to mediate the synergy between radiotherapy and immunotherapy. In this review, we summarize known as well as putative mechanisms underlying the crosstalk between radiotherapy and ferroptosis, discuss the interactions between ferroptosis and other forms of regulated cell death induced by radiotherapy, and explore combination therapeutic strategies targeting ferroptosis in radiotherapy and immunotherapy. This review will provide important frameworks for future investigations of ferroptosis in cancer therapy.
Ferroptosis/immunology*
;
Humans
;
Immunotherapy
;
Neoplasms/therapy*
;
Radiotherapy
Result Analysis
Print
Save
E-mail